Mevacor reverses atherosclerosis in patients without CHD history -- Merck ACAPS study.
Executive Summary
MERCK MEVACOR LABELING INCLUDES STUDY OF USE IN PATIENTS WITH NO CHD, Merck announced April 3. The Asymptomatic Carotid Artery Progression Study showing that Mevacor reverses atherosclerosis in patients with no history of coronary heart disease was approved for inclusion in labeling by FDA on Feb. 9. Merck announced the labeling change following public release of the Bristol-Myers Squibb CARE study, which concluded that Pravachol reduces heart disease in post-MI patients with average cholesterol levels ("The Pink Sheet" April 1, T&G-10).